nicotinic acid 500mg oral powder sachets
special order - nicotinic acid - oral powder - 500mg
nicotinic acid 500mg modified-release tablets
special order - nicotinic acid - modified-release tablet - 500mg
nicotinic acid
troy laboratories pty ltd - nicotinic acid - unknown - nicotinic acid alkaloid active 0.0 - active constituent
nicotinic acid
australian pesticides and veterinary medicines authority - nicotinic acid - unknown - nicotinic acid alkaloid active 0.0 - active constituent
nicotinic acid-darnitsa solution for injection
darnitsa pharmaceutical firm prjsc - nicotinic acid - solution for injection - 10mg/ml
nicotinic acid-zdorovye solution for injection
limited liability company "pharmaceutical company "zdorovye" - nicotinic acid - solution for injection - 10mg/ml
nicotinic acid-darnitsa solution for injection
prjsc «pharmaceutical firm» «darnitsa» - nicotinic acid - solution for injection - 10mg/ml
nicotinic acid-darnitsa
darnitsa pharmaceutical firm prjsc - nicotinic acid - solution for injection - 10mg/ml
pelzont
merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - pelzont is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl)cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).pelzont should be used in patients in combination with 3-hydroxy-3-methylglutaryl-coenzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with pelzont.
tredaptive
merck sharp dohme ltd. - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - tredaptive is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).tredaptive should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with tredaptive.